We are live on ! Find out more
EPRX

Eupraxia Pharmaceuticals
EPRX

8 hedge funds and large institutions have $4.43M invested in Eupraxia Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 8 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

4.85% more ownership

Funds ownership: 0% → 4.85% (+4.8%)

Holders
8
Holders Change
+8
Holders Change %
–
% of All Funds
0.12%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SC
Scotia Capital
Ontario, Canada
+$3.8M
2
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$739K
3
Bank of Montreal
Bank of Montreal
Ontario, Canada
+$137K
4
UBS Group
UBS Group
Switzerland
+$82.3K
5
1WA
180 Wealth Advisors
Washington
+$36.2K

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
SC
1
Scotia Capital
Ontario, Canada
$3.5M +$3.8M +1,367,051 New
Royal Bank of Canada
2
Royal Bank of Canada
Ontario, Canada
$686K +$739K +265,744 New
Bank of Montreal
3
Bank of Montreal
Ontario, Canada
$133K +$137K +49,250 New
UBS Group
4
UBS Group
Switzerland
$76.3K +$82.3K +29,590 New
1WA
5
180 Wealth Advisors
Washington
$34.1K +$36.2K +13,000 New
JP Morgan Chase
6
JP Morgan Chase
New York
$4.88K +$5.26K +1,892 New
FDCDDQ
7
Federation des caisses Desjardins du Quebec
Quebec, Canada
$1.39K +$1.52K +545 New
Toronto Dominion Bank
8
Toronto Dominion Bank
Ontario, Canada
$304 +$328 +118 New

EPRX Hedge Fund Activity: Q2 2024 in Review

8 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in Eupraxia Pharmaceuticals (EPRX) for Q2 2024, worth a combined $4.43M.

Buyers outnumbered sellers: 8 funds opened new EPRX positions and 0 closed out — a net gain of 8 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Scotia Capital, opening a new position worth an estimated $3.8M.

  • 8 institutional investors held Eupraxia Pharmaceuticals (EPRX) as of Q2 2024, up from 0 in Q1 2024.
  • Funds reported $4.43M of Eupraxia Pharmaceuticals stock for Q2 2024.
  • 8 funds opened new Eupraxia Pharmaceuticals positions in Q2 2024 and 0 closed out, a net change of +8 holders.
  • The largest Eupraxia Pharmaceuticals buyer in Q2 2024 was Scotia Capital, an estimated $3.8M added.

Based on aggregated 13F filings for Q2 2024.